NCI’s Research Project Grant pool is likely to receive the largest increase in funding in 16 years, NCI Director Norman “Ned” Sharpless said at an NCI Town Hall meeting April 10.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
